Table 1
Regimens for adjuvant chemotherapy [17]
Regimen | Drugs | Dose (mg/m2) | Route | Day | Interval and cycle |
CMF (PO) | Cyclophophamide | 100 | PO | 1–14 | 28 days, 6 cycles |
Methotrexate | 40 | IV | 1,8 |
5-Fluorouracil | 600 | IV | 1,8 |
CMF (IV) | Cyclophophamide | 600 | IV | 1,8 | 28 days, 6 cycles |
Methotrexate | 40 | IV | 1,8 |
5-Fluorouracil | 600 | IV | 1,8 |
AC | Doxorubicin | 60 | IV | 1 | 21 days, 4 cycles |
Cyclophophamide | 600 | IV | 1 |
EC | Epirubicin | 100 | IV | 1 | 21 days, 8 cycles |
Cyclophophamide | 830 | IV | 1 |
FAC | 5-Fluorouracil | 500 | IV | 1,8 or 1,4 | 21 days, 6 cycles |
Doxorubicin | 50 | IV | 1 |
Cyclophophamide | 500 | IV | 1 |
CAF | Cyclophophamide | 100 | PO | 1–14 | 28 days, 6 cycles |
Doxorubicin | 30 | IV | 1,8 |
5-Fluorouracil | 500 | IV | 1,8 |
FEC | 5-Fluorouracil | 500 | IV | 1,8 | 28 days, 6 cycles |
Epirubicin | 60 | IV | 1,8 |
Cyclophophamide | 75 | PO | 1–14 |
FEC100 | 5-Fluorouracil | 500 | IV | 1,8 | 28 days, 6 cycles |
Epirubicin | 100 | IV | 1,8 |
Cyclophophamide | 75 | PO | 1–14 |
AC→taxane | Doxorubicin | 60 | IV | 1 | 21 days, 8 cycles |
Cyclophophamide | 600 | IV | 1 | 1–4 cycles |
Paclitaxel/docetaxel | 175/75 | IV | 1 | 1–4 cycles |
| | | | 5–8 cycles |
TAC | Docetaxel | 75 | | 1 | 21 days, 6 cycles |
Doxorubicin | 50 | IV | 1 |
Cyclophophamide | 500 | IV | 1 |
TC | Docetaxel | 75 | IV | 1 | 21 days, 4cycles |
Cyclophophamide | 600 | IV | 1 |
PO, per os; IV, Intravenous.